Last reviewed · How we verify

Leuprolide Oral Tablet 4-mg BID

Enteris BioPharma Inc. · Phase 2 active Small molecule

Leuprolide Oral Tablet 4-mg BID is a Small molecule drug developed by Enteris BioPharma Inc.. It is currently in Phase 2 development. Also known as: Ovarest™ 4.0 mg.

At a glance

Generic nameLeuprolide Oral Tablet 4-mg BID
Also known asOvarest™ 4.0 mg
SponsorEnteris BioPharma Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Leuprolide Oral Tablet 4-mg BID

What is Leuprolide Oral Tablet 4-mg BID?

Leuprolide Oral Tablet 4-mg BID is a Small molecule drug developed by Enteris BioPharma Inc..

Who makes Leuprolide Oral Tablet 4-mg BID?

Leuprolide Oral Tablet 4-mg BID is developed by Enteris BioPharma Inc. (see full Enteris BioPharma Inc. pipeline at /company/enteris-biopharma-inc).

Is Leuprolide Oral Tablet 4-mg BID also known as anything else?

Leuprolide Oral Tablet 4-mg BID is also known as Ovarest™ 4.0 mg.

What development phase is Leuprolide Oral Tablet 4-mg BID in?

Leuprolide Oral Tablet 4-mg BID is in Phase 2.

Related